Show simple item record

dc.contributor.authorImburgia, T.M.
dc.contributor.authorShew, M.L.
dc.contributor.authorGravitt, P.E.
dc.contributor.authorKatzenellenbogen, R.A.
dc.date.accessioned2021-04-12T13:11:08Z
dc.date.available2021-04-12T13:11:08Z
dc.date.issued2021
dc.identifier.urihttp://hdl.handle.net/10713/15145
dc.description.abstractSurvivors of childhood cancer and other immunocompromised children are at high risk for the development of secondary human papillomavirus (HPV)-associated cancers. In this overview, the authors examine the epidemiology of vaccine efficacy, the natural history of HPV infections, and accelerated HPV-associated cancer development in these populations. The authors highlight the opportunities for preventive care and future research directives.en_US
dc.description.urihttps://doi.org/10.1097/TP.0000000000003444en_US
dc.language.isoen_USen_US
dc.publisherWolters Kluwer Healthen_US
dc.relation.ispartofTransplantation
dc.subjectsecondary HPV-associated canceren_US
dc.subject.meshCancer Survivoren_US
dc.titleConsiderations for Child Cancer Survivors and Immunocompromised Children to Prevent Secondary HPV-associated Cancersen_US
dc.typeArticleen_US
dc.identifier.doi10.1097/TP.0000000000003444
dc.identifier.pmid32890137


This item appears in the following Collection(s)

Show simple item record